Monoclonal Antibodies and Continuous Processing: A Case Study Examination

While therapeutic monoclonal antibodies (mAbs) have been on the market for over 25 years, it wasn’t until recently that the production of these essential biologics began to move away from traditional methods toward advanced bioproduction techniques like continuous processing. These next-gen bioprocessing technologies have proven to increase production speeds while decreasing costs in many areas. To that end, Chugai Pharmaceutical, a Roche company, has successfully implemented a semi-continuous pilot processing line with support from their collaboration partner, Cytiva.

In this GEN webinar, our experts from Cytiva and Chugai will share their findings around unique collaboration for the continuous processing of mAbs that enabled them to achieve increased productivity and a smaller footprint. A critical success factor has been the high level of customized automation and control in the process. Chugai will discuss their implementation of continuous processing in their “next-generation factory” and the benefits they have seen. Cytiva’s experts will share their thoughts from the Chugai collaboration and discuss implementing a strategic and holistic approach based on critical parameters targeted for improvement. Additionally, experts from Cytiva will consider the risk reduction possibilities created by upstream continuous processing technology. Cytiva will also present a case study performed in collaboration with AdBIOPRO, where an integrated continuous bioprocess was designed to produce acid-sensitive mAb on a pilot scale.

A live Q&A session followed the presentation, offering a chance to pose questions to our expert panelists.

Produced with support from: